Literature DB >> 2461509

The relationship of serotonin to depression in Parkinson's disease.

R Mayeux1, Y Stern, M Sano, J B Williams, L J Cote.   

Abstract

We have previously reported a correlation between depression in patients with idiopathic Parkinson's disease and decreased concentrations of the cerebrospinal fluid content of the serotonin metabolite, 5-HIAA. To further examine this relationship, we repeated the study in a new cohort of patients while they remained on dopaminergic medications, conducted follow-up interviews and examinations in our original cohort, and conducted an open trial of the serotonin precursor, 5-hydroxytryptophan in a group of new patients with depression. We were again able to demonstrate a significant reduction in cerebrospinal 5-HIAA in depressed patients in comparison to controls and patients without depression. Demented patients with Parkinson's disease, particularly those with concurrent depression, had the lowest values of 5-HIAA. No new cases of depression occurred in our original cohort after 2 1/2 years of follow-up, and depression remitted following conventional or experimental treatment in four patients. Depression improved in six of the seven new patients following oral 5-hydroxytryptophan. Three of these patients allowed a repeat lumbar puncture, and the concentration of 5-HIAA increased following 5-hydroxytryptophan. These three studies support our hypothesis that depression in idiopathic Parkinson's disease is associated with a reduction in brain serotonin. However, it also suggests that other factors, biological or environmental, may be causal factors.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2461509     DOI: 10.1002/mds.870030308

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  17 in total

1.  Amino acids and biogenic amines in cerebrospinal fluid of patients with Parkinson's disease.

Authors:  S Engelborghs; B Marescau; P P De Deyn
Journal:  Neurochem Res       Date:  2003-08       Impact factor: 3.996

Review 2.  Depression in Parkinson's disease. Pharmacological characteristics and treatment.

Authors:  T Tom; J L Cummings
Journal:  Drugs Aging       Date:  1998-01       Impact factor: 3.923

Review 3.  Neuropsychiatric aspects of Parkinson's disease: recent advances.

Authors:  Laura Marsh; Ariel Berk
Journal:  Curr Psychiatry Rep       Date:  2003-05       Impact factor: 5.285

4.  Cognitive impairments and depression in Parkinson's disease: a follow up study.

Authors:  S E Starkstein; P L Bolduc; H S Mayberg; T J Preziosi; R G Robinson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-07       Impact factor: 10.154

5.  Parkinson's disease and depression: evidence for an alteration of the basal limbic system detected by transcranial sonography.

Authors:  T Becker; G Becker; J Seufert; E Hofmann; K W Lange; M Naumann; A Lindner; H Reichmann; P Riederer; H Beckmann; K Reiners
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-11       Impact factor: 10.154

6.  Antidepressant treatment of veterans with Parkinson's disease and depression: analysis of a national sample.

Authors:  Peijun Chen; Helen C Kales; Daniel Weintraub; Frederic C Blow; Lan Jiang; Alan M Mellow
Journal:  J Geriatr Psychiatry Neurol       Date:  2007-09       Impact factor: 2.680

Review 7.  Dopamine and depression.

Authors:  A S Brown; S Gershon
Journal:  J Neural Transm Gen Sect       Date:  1993

Review 8.  Biochemical and pathological correlates of cognitive and behavioural change in DLB/PDD.

Authors:  Paul T Francis
Journal:  J Neurol       Date:  2009-08       Impact factor: 4.849

Review 9.  Advances in the molecular characterization of tryptophan hydroxylase.

Authors:  S M Mockus; K E Vrana
Journal:  J Mol Neurosci       Date:  1998-06       Impact factor: 3.444

10.  The role of serotonin in the pathogenesis and clinical presentations of migraine attacks.

Authors:  K F Izzati-Zade
Journal:  Neurosci Behav Physiol       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.